LLY

Eli Lilly and Co

Add to Watchlist

Advanced Chart

757.390

+24.100(+3.290%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

758.870

Open

740.000

VWAP

752.22

Vol

4.60M

Mkt Cap

717.81B

Low

737.550

Amount

3.46B

EV/EBITDA(TTM)

33.11

Total Shares

950.41M

713.54B

EV/OCF(TTM)

76.58

P/S(TTM)

13.19

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

14.32B

+26.73%

5.515

+40.68%

15.37B

+34.38%

6.123

+418.91%

17.00B

+25.63%

6.851

+28.78%

Estimates Revision

The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 0.8% over the past three months. During the same period, the stock price has changed by -11.64%.

Revenue Estimates for FY2025

Revise Upward

+0.8%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.34%

In Past 3 Month

Stock Price

Go Down

-11.64%

In Past 3 Month

19 Analyst Rating

29.52% Upside

Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 981.00 USD with a low forecast of 700.00 USD and a high forecast of 1124 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Buy

0 Hold

1 Sell

Strong Buy

29.52% Upside

Current: 757.390

Low

700.00

Averages

981.00

High

1124

29.52% Upside

Current: 757.390

Low

700.00

Averages

981.00

High

1124

UBS

Trung Huynh

Strong Buy

Maintains

$1,100 → $1,050

2025-05-02

Reason

UBS

Trung Huynh

Price Target

$1,100 → $1,050

2025-05-02

Maintains

Strong Buy

Reason

UBS analyst Trung Huynh lowered the firm's price target on Eli Lilly to $1,050 from $1,100 and keeps a Buy rating on the shares. UBS thinks the selloff is overdone in light of robust GLP franchise sales.

HSBC

Rajesh Kumar

Strong Buy

Sell

Downgrades

$1,150 → $700

2025-04-28

Reason

HSBC

Rajesh Kumar

Price Target

$1,150 → $700

2025-04-28

Downgrades

Strong Buy

Sell

Reason

Cantor Fitzgerald

Carter Gould

Buy

Initiates

$975

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$975

2025-04-22

Initiates

Buy

Reason

Cantor Fitzgerald initiated coverage of Eli Lilly with an Overweight rating and $975 price target.

Guggenheim

Seamus Fernandez

Strong Buy

Maintains

$973 → $928

2025-04-14

Reason

Guggenheim

Seamus Fernandez

Price Target

$973 → $928

2025-04-14

Maintains

Strong Buy

Reason

Guggenheim lowered the firm's price target on Eli Lilly to $928 from $973 and keeps a Buy rating on the shares. The firm is updating its model ahead of Q1 earnings due to be reported May 1. The tirzepatide franchise remains top of mind and the current prescription trajectory suggests the firm's and consensus 2025 numbers are "comfortably achievable," the analyst tells investors in a preview.

Morgan Stanley

Terence Flynn

Buy

Maintains

$1,146 → $1,124

2025-04-09

Reason

Morgan Stanley

Terence Flynn

Price Target

$1,146 → $1,124

2025-04-09

Maintains

Buy

Reason

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly's (LLY) branded tirzepatide and generic liraglutide, Morgan Stanley analyst Craig Hettenbach said an expanding offering could help ease some concerns over the company's target of $725M in weight loss revenue in 2025. However, margins that Hims realizes for branded tirzepatide are likely well below their compounded GLP-1 products, the analyst tells investors. The firm, which argues that the durability of personalized compounded GLP-1 and momentum in oral weight loss drugs remain the biggest factors in determining whether Hims will deliver on its revenue guidance, keeps an Equal Weight rating and $60 price target on Hims shares.

Goldman Sachs

Asad Haider

Hold

Strong Buy

Upgrades

$892 → $888

2025-04-08

Reason

Goldman Sachs

Asad Haider

Price Target

$892 → $888

2025-04-08

Upgrades

Hold

Strong Buy

Reason

Goldman Sachs upgraded Eli Lilly to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name. Following the recent selloff, Eli Lilly shares offer a "compelling entry point into the sector's premier topline grower," the analyst tells investors in a research note. The firm believes the company "will maintain its pole position" as the leader in the anti-obesity medication market, which Goldman says it set to triple in size from$28B today to $95B by 2030.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 29.33, compared to its 5-year average forward P/E of 39.11. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

39.11

Current PE

29.33

Overvalued PE

52.13

Undervalued PE

26.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

29.29

Current EV/EBITDA

21.82

Overvalued EV/EBITDA

37.88

Undervalued EV/EBITDA

20.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

10.39

Current PS

10.23

Overvalued PS

13.77

Undervalued PS

7.01

Financials

Annual

Quarterly

FY2025Q1

YoY :

+45.17%

12.73B

Total Revenue

FY2025Q1

YoY :

+102.40%

5.30B

Operating Profit

FY2025Q1

YoY :

+23.02%

2.76B

Net Income after Tax

FY2025Q1

YoY :

+23.39%

3.06

EPS - Diluted

FY2025Q1

YoY :

-2024.16%

-1.60B

Free Cash Flow

FY2025Q1

YoY :

+2.00%

82.53

Gross Profit Margin - %

FY2025Q1

YoY :

-76.11%

-2.59

FCF Margin - %

FY2025Q1

YoY :

-15.25%

21.68

Net Margin - %

FY2025Q1

YoY :

+32.56%

25.24

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

205.1M

USD

3-6

Months

2.2B

USD

6-9

Months

23.3M

USD

0-12

Months

1.3B

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 163841.95% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

182.5K

Volume

6-9

Months

0.0

Volume

0-12

Months

294.9K

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.4M

Volume

Months

6-9

1.5K

Volume

Months

0-12

626.3K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

129.0K

USD

3-6

Months

163.0K

USD

6-9

Months

121.5K

USD

0-12

Months

24.0K

USD

Bought

0-3

272.0K

USD

Months

3-6

91.0K

USD

Months

6-9

32.5K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

205.1M

USD

3-6

Months

2.2B

USD

6-9

Months

23.3M

USD

0-12

Months

1.3B

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

LLY News & Events

Events Timeline

2025-05-14 (ET)

2025-05-14

06:29:46

U.S. biotech companies debate relocating trials outside U.S., Reuters reports

2025-05-13 (ET)

2025-05-13

06:22:08

Trump's drug-price crackdown may lead to minor concessions, WSJ reports

2025-05-12 (ET)

2025-05-12

10:59:57

White House publishes Trump executive order aimed at lowering drug prices

News

7.5

05-15Benzinga

PinnedEli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact

4.5

17:13 PMYahoo Finance

Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic

8.0

17:08 PMBenzinga

3 Stocks That Will Profit From Trump's Drug Price Cut

People Also Watch

UNH

UnitedHealth Group Inc

Costco Wholesale Corp

Berkshire Hathaway Inc

FAQ

What is Eli Lilly and Co (LLY) stock price today?

The current price of LLY is 757.39 USD — it has increased 3.29 % in the last trading day.

LLY

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LLY News & Events

Events Timeline

News

People Also Watch

FAQ

What is Eli Lilly and Co (LLY) stock price today?

What is Eli Lilly and Co (LLY)'s business?

What is the price predicton of LLY Stock?

What is Eli Lilly and Co (LLY)'s revenue for the last quarter?

What is Eli Lilly and Co (LLY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Eli Lilly and Co (LLY)'s fundamentals?

How many employees does Eli Lilly and Co (LLY). have?

What is Eli Lilly and Co (LLY) market cap?